Related references
Note: Only part of the references are listed.Outcome of allogeneic hematopoietic stem cell transplantation for cytogenetically normal AML and identification of high-risk subgroup using WT1 expression in association with NPM1 and FLT3-ITD mutations
Jae-Ho Yoon et al.
GENES CHROMOSOMES & CANCER (2015)
Prognostic importance of expression of the Wilms' tumor 1 gene in newly diagnosed acute promyelocytic leukemia
Anna Hecht et al.
LEUKEMIA & LYMPHOMA (2015)
A molecular risk score integrating BAALC, ERG and WT1 expression levels for risk stratification in acute promyelocytic leukemia
Anna Hecht et al.
LEUKEMIA RESEARCH (2015)
Long-term WT1 peptide vaccination for patients with acute myeloid leukemia with minimal residual disease
A. Tsuboi et al.
LEUKEMIA (2012)
Potential role of adoptively transferred allogeneic WT1-specific CD4(+) and CD8(+) T lymphocytes for the sustained remission of refractory AML
Y-J Kim et al.
BONE MARROW TRANSPLANTATION (2010)
Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy:: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group
Miguel A. Sanz et al.
BLOOD (2008)
Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy:: a multicenter study by the PETHEMA group
MA Sanz et al.
BLOOD (2004)
Share Paper
